dr. borchmann on next steps with tisagenlecleucel in dlbcl
Published 6 years ago • 169 plays • Length 1:59Download video MP4
Download video MP3
Similar videos
-
1:17
dr. borchmann discusses the updated analysis of juliet in dlbcl
-
0:39
dr. flinn on fda approval of tisagenlecleucel in dlbcl
-
1:58
dr. maziarz on sustained responses with tisagenlecleucel in dlbcl
-
1:09
car t-cell therapy offers hope in dlbcl
-
1:43
dr. maziarz discusses promise of tisagenlecleucel in dlbcl
-
1:18
dr. maziarz on unanswered questions with car t-cell therapy in dlbcl
-
3:51
long-term outcomes on tisagenlecleucel: 4 years in dlbcl and fl
-
2:07
dr. hou on polatuzumab vedotin in dlbcl
-
5:51
updated juliet results for tisagenlecleucel in dlbcl
-
5:08
tisagenlecleucel for relapsed/refractory all
-
0:43
the unmet need in dlbcl
-
8:54
stephen j. schuster, md: tisagenlecleucel promising in relapsed/refractory dlbcl
-
6:04
tisagenlecleucel shows no efs improvement on standard of care in 2l for aggressive b-cell nhl
-
1:03
tatyana feldman, md, on unmet needs in peripheral t-cell lymphoma (ptcl)
-
1:33
btki inhibitors in the treatment of b-cell lymphoma - introduction
-
5:51
latest results from juliet: tisagenlecleucel in adults with dlbcl
-
2:42
the role of ibrutinib in dlbcl and the value of next-generation btk inhibitors
-
4:06
lymphoma cellular therapy update
-
1:24
tisagenlecleucel for r/r dlbcl